By placing an order the buyer agrees to Zedira's General Trade Conditions (GTC).
Products
Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.
News
Dr. Falk Pharma and Zedira announce start of the phase 2a proof of concept study of ZED1227 for the treatment of non-alcoholic fatty liver disease (NAFLD)
Zedira publication - Features of ZED1227: The First-In-Class Tissue Transglutaminase Inhibitor Undergoing Clinical Evaluation for the Treatment of Celiac Disease
Dr. Falk Pharma and Zedira announce start of the phase 2b real-life study of ZED1227 for the treatment of Celiac Disease
Dr. Falk Pharma and Zedira announce successful completion of the phase 2a proof-of-concept study of ZED1227 for the treatment of Celiac Disease
Dr. Falk Pharma und Zedira verkünden den erfolgreichen Abschluss der Phase 2a-Studie mit ZED1227 zur Behandlung von Zöliakie
Reversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis
Press release: Zedira announces ISO 9001:2015 certification
Blog
DZG Aktuell: „Aufruf zur Teilnahme an einer weiteren Wirksamkeitsstudie mit dem Studienmedikament ZED1227“
Design of Oral FXIIIa Blockers as Safer Anticoagulants – Mission Impossible?
Microbial transglutaminase (MTG) enables efficient and site-specific conjugation to native antibodies without the need of antibody engineering